ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer - Episode 10
Comparing Treatment Schedules: Ifinatamab Deruxtecan vs Amrubicin, Topotecan, and Lurbinectedin in SCLC
Panelists discuss how the treatment schedule of ifinatamab deruxtecan at 12 mg/kg intravenouslyIV Q3W once every 3 weeks may compare favorably to established regimens like amrubicin, topotecan, and lurbinectedin for relapsed small cell lung cancer, while also exploring potential dose adjustments, immunogenicity concerns, and the synergistic effects when combined with atezolizumab and carboplatin.
Video content above is prompted by the following:[All Faculty ] How does a treatment schedule of 12 mg/kg IV Q3Wintravenously (IV) once every 3 weeks compare with that of:
►amrubicin ([[(Calsed]) aminoanthracycline)]: 45 mg/m2 IV iInfusion QD x 3 days Q3W ([Japan)]
►topotecan ([[(Hycamtin]) topoisomerase inhibitor)]: 1.5 mg/m2 IV infusion QD, Ddays 1 to -5 Q3W
►lurbinectedin ([[(Zepzelca]) alkylating agent)]: 3.2 mg/m2 IV infusion once every 3 weeksQ3W
• For small cell lung cancer (SCLC) that has relapsed after 2two or more lines of prior therapy, do you anticipate the RP2D recommended phase 2 dose to be 8 mg/kg Q3W once every 3 weeks or 12 mg/kg Q3Wonce every 3 weeks?
o Is there an opportunity to dose-reduce ifinatamab deruxtecan, as required, without compromising efficacy?
• What is the potential for immunogenicity with this particular ADCantibody-drug conjugate, and which treatment-related adverse events would most concern you?
5. [All Faculty] In your opinion, how might ifinatamab deruxtecan (I-DXd) synergize with
atezolizumab + carboplatin as first-line induction or maintenance therapy in patients with
extensive-stage ES-SCLC?
Related Content:
